TransMedics Group (NASDAQ:TMDX) Trading Down 4.4% – Should You Sell?

TransMedics Group, Inc. (NASDAQ:TMDX) shares fell 4.4% during trading on Wednesday . The company traded as low as $62.80 and last traded at $62.80. 598,790 shares were traded during trading, a decline of 43% from the average session volume of 1,047,481 shares. The stock had previously closed at $65.71.

Analysts Set New Price Targets

A number of brokerages have commented on TMDX. TD Cowen cut their price target on shares of TransMedics Group from $175.00 to $120.00 and set a “buy” rating for the company in a research note on Monday, November 18th. Piper Sandler cut their target price on shares of TransMedics Group from $110.00 to $90.00 and set an “overweight” rating for the company in a research note on Wednesday, December 11th. Robert W. Baird cut their target price on shares of TransMedics Group from $150.00 to $120.00 and set an “outperform” rating for the company in a research note on Wednesday, December 11th. Needham & Company LLC reiterated a “hold” rating on shares of TransMedics Group in a research note on Wednesday, December 11th. Finally, Baird R W upgraded shares of TransMedics Group to a “strong-buy” rating in a research note on Tuesday, September 24th. Three research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $122.70.

TransMedics Group Trading Down 7.4 %

The company has a quick ratio of 7.33, a current ratio of 8.20 and a debt-to-equity ratio of 2.42. The firm has a market cap of $2.04 billion, a price-to-earnings ratio of 64.77 and a beta of 2.06. The business’s fifty day moving average is $92.92 and its two-hundred day moving average is $130.29.

TransMedics Group (NASDAQ:TMDX) last released its earnings results on Monday, October 28th. The company reported $0.12 EPS for the quarter, missing analysts’ consensus estimates of $0.29 by ($0.17). TransMedics Group had a return on equity of 18.74% and a net margin of 8.14%. The business had revenue of $108.76 million for the quarter, compared to analyst estimates of $115.00 million. During the same period in the prior year, the firm posted ($0.12) EPS. TransMedics Group’s revenue was up 63.7% on a year-over-year basis. Equities analysts anticipate that TransMedics Group, Inc. will post 1 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, insider Tamer I. Khayal sold 1,084 shares of the business’s stock in a transaction on Monday, December 2nd. The shares were sold at an average price of $86.40, for a total value of $93,657.60. Following the completion of the transaction, the insider now owns 20,843 shares of the company’s stock, valued at $1,800,835.20. The trade was a 4.94 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Waleed H. Hassanein sold 8,625 shares of the business’s stock in a transaction on Tuesday, October 15th. The shares were sold at an average price of $132.71, for a total transaction of $1,144,623.75. Following the completion of the transaction, the chief executive officer now directly owns 61,643 shares of the company’s stock, valued at $8,180,642.53. This trade represents a 12.27 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 19,417 shares of company stock valued at $2,240,738. Company insiders own 7.00% of the company’s stock.

Hedge Funds Weigh In On TransMedics Group

Several institutional investors and hedge funds have recently made changes to their positions in TMDX. State of Alaska Department of Revenue bought a new stake in TransMedics Group in the 3rd quarter valued at $2,560,000. Charles Schwab Investment Management Inc. lifted its position in TransMedics Group by 2.5% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 271,694 shares of the company’s stock valued at $42,656,000 after acquiring an additional 6,634 shares in the last quarter. Zacks Investment Management bought a new stake in TransMedics Group in the 3rd quarter valued at $1,607,000. Vaughan Nelson Investment Management L.P. lifted its position in TransMedics Group by 24.3% in the 3rd quarter. Vaughan Nelson Investment Management L.P. now owns 329,010 shares of the company’s stock valued at $51,654,000 after acquiring an additional 64,360 shares in the last quarter. Finally, Connor Clark & Lunn Investment Management Ltd. lifted its position in TransMedics Group by 665.1% in the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 74,625 shares of the company’s stock valued at $11,716,000 after acquiring an additional 64,872 shares in the last quarter. Institutional investors and hedge funds own 99.67% of the company’s stock.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.